📰 Equal Life News
Page 3 - Equal Life News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Equal Life. Real-time updates on events, politics, business and more.
August 3, 2022
People with diabetes may experience an array of emotions as they manage their condition, but improving nutrition is one area within their control that can have a positive impact on their quality of life.
July 27, 2022
Healthcare providers’ usage of a dashboard that provided medication ingestion information impacted treatment decisions and clinical assessments.
July 26, 2022
Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell diseaseSOUTH SAN FRANCISCO, Calif., July
June 24, 2022
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced a New Drug Application (NDA) for...
May 5, 2022
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present 12-week results from the pivotal Phase 3...
May 5, 2022
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present 12-week results from the pivotal Phase 3...
March 15, 2022
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced topline results from the ongoing Phase 3...
March 14, 2022
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced topline results from the ongoing Phase 3...
January 27, 2022
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) today announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific opinion
January 27, 2022
Investegate announcements from Global Blood Therapeutics, Inc, Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease